You can buy or sell HRTX and other stocks, options, ETFs, and crypto commission-free!
Heron Therapeutics, Inc. Common Stock, also called Heron Therapeutics, is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. Read More The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMay 9
Heron Therapeutics Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -70.21% and 15.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireMay 8
Heron Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
SAN DIEGO, May 8, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, at 11:35 a.m. PDT at the Encore Hotel in L...
Yahoo FinanceMay 8
When Will Heron Therapeutics, Inc. (NASDAQ:HRTX) Breakeven?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Heron Therapeutics, Inc.'s (NASDAQ:HRTX): Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. On 31 December 2018, the US$1.3b market-cap posted a loss of -US$178.8m for its most recent financial year. As path to profitability is the topic on HRTX’s investors mind, I’ve decided to gauge market sentiment. In this article, ...
Expected Aug 8, Pre-Market